Aveanna Healthcare (NASDAQ:AVAH) Major Shareholder Paul Vigano Sells 14,500,002 Shares of Stock

Posted by Brian Himes on Aug 25th, 2026

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH – Get Free Report) major shareholder Paul Vigano sold 14,500,002 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $11.50, for a total transaction of $166,750,023.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Aveanna Healthcare Stock Up 4.1%

Shares of NASDAQ AVAH opened at $13.70 on Tuesday. The company has a debt-to-equity ratio of 4.47, a quick ratio of 1.16 and a current ratio of 1.16. The firm has a market capitalization of $2.99 billion, a price-to-earnings ratio of 11.14, a PEG ratio of 0.92 and a beta of 1.90. The stock has a 50 day moving average price of $9.71 and a 200 day moving average price of $7.95. Aveanna Healthcare Holdings Inc. has a 52-week low of $5.93 and a 52-week high of $13.98.

Aveanna Healthcare (NASDAQ:AVAH – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.17 by $0.05. The company had revenue of $670.48 million for the quarter, compared to the consensus estimate of $638.61 million. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%. Sell-side analysts expect that Aveanna Healthcare Holdings Inc. will post 0.68 earnings per share for the current year.

Hedge Funds Weigh In On Aveanna Healthcare

A number of large investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Aveanna Healthcare by 252.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock valued at $27,000 after purchasing an additional 2,400 shares during the last quarter. C M Bidwell & Associates Ltd. purchased a new position in Aveanna Healthcare during the 2nd quarter worth $69,000. Summit Securities Group LLC purchased a new position in Aveanna Healthcare during the 1st quarter worth $53,000. Quantbot Technologies LP acquired a new position in Aveanna Healthcare during the 2nd quarter valued at about $43,000. Finally, Freestone Grove Partners LP acquired a new stake in Aveanna Healthcare in the second quarter worth about $73,000. 87.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AVAH. UBS Group upped their price objective on shares of Aveanna Healthcare from $8.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. Stephens raised shares of Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $10.00 to $11.00 in a research report on Friday, May 15th. Royal Bank Of Canada boosted their price target on shares of Aveanna Healthcare from $10.00 to $16.00 and gave the company an “outperform” rating in a report on Monday. Wall Street Zen downgraded shares of Aveanna Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 15th. Finally, Barclays boosted their price objective on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Aveanna Healthcare has an average rating of “Moderate Buy” and an average price target of $12.89.

Check Out Our Latest Report on Aveanna Healthcare

Key Aveanna Healthcare News

Here are the key news stories impacting Aveanna Healthcare this week:

Positive Sentiment: Royal Bank of Canada raised its price target from $10 to $16 and upgraded its rating to “outperform,” implying additional upside from the stock’s recent trading level. Benzinga analyst coverage
Positive Sentiment: Truist Financial lifted its price target from $11 to $15 while maintaining a “hold” rating. The higher target reflects improved valuation expectations, even though Truist remains cautious on the shares. Benzinga analyst coverage
Negative Sentiment: Insiders and major shareholders disclosed approximately 48.6 million shares of sales at an average price of $11.50, worth roughly $558.5 million. Sellers included Paul R. Vigano, Robert M. Williams Jr., and J.H. Whitney Equity Partners V, as well as CEO Jeff Shaner, director Rodney D. Windley, and insider Edwin C. Reisz. Although the sellers retained sizable positions, the volume of stock coming to market may pressure AVAH and raise questions about shareholder confidence. SEC insider transaction filing

Aveanna Healthcare Company Profile

(Get Free Report)

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.